*DJ Nestle Now Has Around 84% of Aimmune Therapeutics Shares
(MORE TO FOLLOW) Dow Jones Newswires
October 13, 2020 01:18 ET (05:18 GMT)
*DJ Nestle's Subsidiary SPN MergerSub Offered $34.5 for Each Aimmune Therapeutics Share Not Owned by Nestle
(MORE TO FOLLOW) Dow Jones Newswires
October 13, 2020 01:21 ET (05:21 GMT)
*DJ Nestle: Minimum Tender Condition Has Been Satisfied
(MORE TO FOLLOW) Dow Jones Newswires
October 13, 2020 01:22 ET (05:22 GMT)
*DJ Nestle Wants to Merge SPN MergerSub Subsidiary With Aimmune Therapeutics
(MORE TO FOLLOW) Dow Jones Newswires
October 13, 2020 01:24 ET (05:24 GMT)
DJ Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With Subsidiary
By Joshua Kirby
Nestle SA said Tuesday that it has bought a number of shares in Aimmune Therapeutics Inc., taking its holding in the pharmaceutical company to 84%.
The Swiss food-and-beverage conglomerate said its wholly-owned subsidiary SPN MergerSub had purchased around 43.4 million shares via a tender offer at a price of $34.50 per share. Added to the shares already owned by Nestle and its subsidiaries, it represents around 84% of the outstanding shares in Aimmune Therapeutics, the company said.
SPN MergerSub will be merged with Aimmune Therapeutics, which will continue as the surviving corporation, Nestle said.
Write to Joshua Kirby at joshua.kirby@dowjones.com
(END) Dow Jones Newswires
October 13, 2020 01:45 ET (05:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.